Bristol Myers Squibb announced positive topline results from the phase 3 CheckMate -648 trial evaluating treatment with Opdivo (nivolumab) plus chemotherapy or Opdivo plus Yervoy (ipilimumab) in ...

Opdivo is the first and only PD-1/L1 inhibitor to demonstrate superior first-line efficacy in upper GI cancers across histologies and tumor locations Statistically significant overall survival benefit ...

CheckMate -648 is one of four positive Phase 3 trials in which Opdivo or Opdivo-based treatment combinations demonstrated a significant benefit for patients with upper gastrointestinal cancers The ...

Please provide your email address to receive an email when new articles are posted on . The addition of nivolumab to chemotherapy or ipilimumab significantly improved OS compared with chemotherapy ...

Swallowable sampling device combined with methylation biomarker panel IDs Barrett esophagus. The approvals are based on data from the phase 3 CheckMate-648 trial, which included 970 adults with ...

Based on the Phase 3 CheckMate-8HW trial, Opdivo plus Yervoy demonstrated reduction in the risk of disease progression or death by 79% vs. chemotherapy in the first-line setting and by 38% vs. Opdivo ...

The FDA approved nivolumab plus fluoropyrimidine- and platinum-containing chemotherapy and nivolumab plus ipilimumab as first-line treatments for adults with unresectable advanced or metastatic ...

Opdivo was the first PD-1 inhibitor to show durable responses in patients with esophageal squamous cell carcinoma. Patients with previously untreated, unresectable, advanced esophageal squamous cell ...

Immunotherapy-containing combinations significantly improved survival in advanced esophageal cancer as compared with standard chemotherapy, a large randomized trial showed. Median overall survival (OS ...

Bristol Myers Squibb announced the phase 3 CheckMate -9DW trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for patients with advanced hepatocellular carcinoma ...